Showing results (61-70 of 126) with videos related to

Sort By:
Pageof 13
Blood|July 10, 2014
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupMarie-Anne Hospital, Thomas Prebet, Sarah Bertoli, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
International Journal of Molecular Sciences|December 29, 2019
Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid LeukemiaThomas Cluzeau, Nathan Furstoss, Coline Savy, et al.
Oncotarget|May 18, 2017
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemiaValérie Vidal, Guillaume Robert, Laure Goursaud, et al.
Experimental Hematology & Oncology|April 1, 2026
Dual targeting of GPX4 and TXNRD1 triggers eradication of AML cells through induction of apoptosis and ferroptosisCécile Favreau, Maxence Bourgoin, Coline Savy, et al.
Bone Marrow Transplantation|December 19, 2020
Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC studyDavid Beauvais, Elodie Drumez, Didier Blaise, et al.
Autophagy|June 2, 2015
The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMMLSandrine Obba, Zoheir Hizir, Laurent Boyer, et al.
Leukemia Research|December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patientsRaphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
Leukemia|June 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemiaDelphine Lebon, Audrey Da Rocha, Bruno Cassinat, et al.
Leukemia Research|January 16, 2017
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFALining Wang, Emmanuel Raffoux, Xavier Thomas, et al.
Pageof 13